Literature DB >> 15870199

A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.

Gregory S Hageman1, Don H Anderson, Lincoln V Johnson, Lisa S Hancox, Andrew J Taiber, Lisa I Hardisty, Jill L Hageman, Heather A Stockman, James D Borchardt, Karen M Gehrs, Richard J H Smith, Giuliana Silvestri, Stephen R Russell, Caroline C W Klaver, Irene Barbazetto, Stanley Chang, Lawrence A Yannuzzi, Gaetano R Barile, John C Merriam, R Theodore Smith, Adam K Olsh, Julie Bergeron, Jana Zernant, Joanna E Merriam, Bert Gold, Michael Dean, Rando Allikmets.   

Abstract

Age-related macular degeneration (AMD) is the most frequent cause of irreversible blindness in the elderly in developed countries. Our previous studies implicated activation of complement in the formation of drusen, the hallmark lesion of AMD. Here, we show that factor H (HF1), the major inhibitor of the alternative complement pathway, accumulates within drusen and is synthesized by the retinal pigmented epithelium. Because previous linkage analyses identified chromosome 1q25-32, which harbors the factor H gene (HF1/CFH), as an AMD susceptibility locus, we analyzed HF1 for genetic variation in two independent cohorts comprised of approximately 900 AMD cases and 400 matched controls. We found association of eight common HF1 SNPs with AMD; two common missense variants exhibit highly significant associations (I62V, chi2 = 26.1 and P = 3.2 x 10(-7) and Y402H, chi2 = 54.4 and P = 1.6 x 10(-13)). Haplotype analysis reveals that multiple HF1 variants confer elevated or reduced risk of AMD. One common at-risk haplotype is present at a frequency of 50% in AMD cases and 29% in controls [odds ratio (OR) = 2.46, 95% confidence interval (1.95-3.11)]. Homozygotes for this haplotype account for 24% of cases and 8% of controls [OR = 3.51, 95% confidence interval (2.13-5.78)]. Several protective haplotypes are also identified (OR = 0.44-0.55), further implicating HF1 function in the pathogenetic mechanisms underlying AMD. We propose that genetic variation in a regulator of the alternative complement pathway, when combined with a triggering event, such as infection, underlie a major proportion of AMD in the human population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870199      PMCID: PMC1088171          DOI: 10.1073/pnas.0501536102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  A potential role for immune complex pathogenesis in drusen formation.

Authors:  L V Johnson; S Ozaki; M K Staples; P A Erickson; D H Anderson
Journal:  Exp Eye Res       Date:  2000-04       Impact factor: 3.467

Review 2.  Regulation of the complement membrane attack pathway.

Authors:  B P Morgan
Journal:  Crit Rev Immunol       Date:  1999       Impact factor: 2.214

Review 3.  Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage?

Authors:  P F Zipfel
Journal:  Trends Immunol       Date:  2001-07       Impact factor: 16.687

Review 4.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

Review 5.  Complement factor H and hemolytic uremic syndrome.

Authors:  P F Zipfel; C Skerka; J Caprioli; T Manuelian; H H Neumann; M Noris; G Remuzzi
Journal:  Int Immunopharmacol       Date:  2001-03       Impact factor: 4.932

6.  Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease.

Authors:  R F Mullins; S R Russell; D H Anderson; G S Hageman
Journal:  FASEB J       Date:  2000-05       Impact factor: 5.191

7.  A cell culture medium that supports the differentiation of human retinal pigment epithelium into functionally polarized monolayers.

Authors:  J Hu; D Bok
Journal:  Mol Vis       Date:  2001-02-07       Impact factor: 2.367

8.  Further evidence for an association of ABCR alleles with age-related macular degeneration. The International ABCR Screening Consortium.

Authors:  R Allikmets
Journal:  Am J Hum Genet       Date:  2000-07-03       Impact factor: 11.025

Review 9.  Immunological and aetiological aspects of macular degeneration.

Authors:  P L Penfold; M C Madigan; M C Gillies; J M Provis
Journal:  Prog Retin Eye Res       Date:  2001-05       Impact factor: 21.198

10.  Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells.

Authors:  G S Hageman; R F Mullins; S R Russell; L V Johnson; D H Anderson
Journal:  FASEB J       Date:  1999-03       Impact factor: 5.191

View more
  823 in total

Review 1.  Dynamic control of the complement system by modulated expression of regulatory proteins.

Authors:  Joshua M Thurman; Brandon Renner
Journal:  Lab Invest       Date:  2010-10-04       Impact factor: 5.662

2.  Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Yu Kawashima; Akio Oishi; Akitaka Tsujikawa; Kenji Yamashiro; Masahiro Miyake; Naoko Ueda-Arakawa; Munemitsu Yoshikawa; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-13       Impact factor: 3.117

3.  C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration.

Authors:  Imran A Bhutto; Takayuki Baba; Carol Merges; Vikash Juriasinghani; D Scott McLeod; Gerard A Lutty
Journal:  Br J Ophthalmol       Date:  2011-06-01       Impact factor: 4.638

4.  Use of time-resolved FRET to validate crystal structure of complement regulatory complex between C3b and factor H (N terminus).

Authors:  Isabell C Pechtl; Robert K Neely; David T F Dryden; Anita C Jones; Paul N Barlow
Journal:  Protein Sci       Date:  2011-12       Impact factor: 6.725

5.  High-density lipoproteins are a potential therapeutic target for age-related macular degeneration.

Authors:  Una L Kelly; Daniel Grigsby; Martha A Cady; Michael Landowski; Nikolai P Skiba; Jian Liu; Alan T Remaley; Mikael Klingeborn; Catherine Bowes Rickman
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

Review 6.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

7.  Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab.

Authors:  Kaan Gulleroglu; Kibriya Fidan; Veysel S Hançer; Umut Bayrakci; Esra Baskin; Oguz Soylemezoglu
Journal:  Pediatr Nephrol       Date:  2013-02-07       Impact factor: 3.714

8.  Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.

Authors:  Zohar Yehoshua; Carlos Alexandre de Amorim Garcia Filho; Renata Portella Nunes; Giovanni Gregori; Fernando M Penha; Andrew A Moshfeghi; Kang Zhang; Srinivas Sadda; William Feuer; Philip J Rosenfeld
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

9.  Genetic loci that control the size of laser-induced choroidal neovascularization.

Authors:  Kei Nakai; Michael S Rogers; Takashi Baba; Taisaku Funakoshi; Amy E Birsner; Dema S Luyindula; Robert J D'Amato
Journal:  FASEB J       Date:  2009-02-23       Impact factor: 5.191

Review 10.  Age-related macular degeneration: genetics and biology coming together.

Authors:  Lars G Fritsche; Robert N Fariss; Dwight Stambolian; Gonçalo R Abecasis; Christine A Curcio; Anand Swaroop
Journal:  Annu Rev Genomics Hum Genet       Date:  2014-04-16       Impact factor: 8.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.